QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
Free Trial

RAPT Therapeutics (RAPT) Stock Forecast & Price Target

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)
Free rapt Stock Alerts
$8.12
-0.42 (-4.92%)
(As of 01:33 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

RAPT Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 12 Analyst Ratings

Analysts' Consensus Price Target

$25.67
216.09% Upside
High Forecast$41.00
Average Forecast$25.67
Low Forecast$10.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.67$25.89$36.33$41.44
Predicted Upside216.09% Upside69.15% Upside90.24% Upside105.70% Upside
Get RAPT Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

RAPT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RAPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

RAPT Therapeutics Stock vs. The Competition

TypeRAPT TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside200.55% Upside882.30% Upside11.22% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingNeutral
3/27/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$15.00 ➝ $13.00+51.52%
2/22/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$61.00 ➝ $10.00-1.77%
2/21/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
2/21/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$35.00 ➝ $13.00+51.34%
2/21/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform$42.00 ➝ $10.00+45.56%
2/20/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOverweight ➝ Neutral
2/16/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$39.00+52.64%
9/14/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$34.00+77.64%
8/14/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$28.00 ➝ $31.00+29.33%
8/8/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$40.00+77.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:53 PM ET.

RAPT Price Target - Frequently Asked Questions

What is RAPT Therapeutics's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for RAPT Therapeutics stock is Moderate Buy based on the current 6 hold ratings and 6 buy ratings for RAPT. The average twelve-month price prediction for RAPT Therapeutics is $25.67 with a high price target of $41.00 and a low price target of $10.00. Learn more on RAPT's analyst rating history.

Do Wall Street analysts like RAPT Therapeutics more than its competitors?

Analysts like RAPT Therapeutics less than other Medical companies. The consensus rating score for RAPT Therapeutics is 2.50 while the average consensus rating score for medical companies is 2.68. Learn more on how RAPT compares to other companies.

Is RAPT Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, RAPT Therapeutics's stock had 6 downgrades by analysts.

Does RAPT Therapeutics's stock price have much upside?

According to analysts, RAPT Therapeutics's stock has a predicted upside of 65.52% based on their 12-month stock forecasts.

What analysts cover RAPT Therapeutics?

RAPT Therapeutics has been rated by Barclays, Cantor Fitzgerald, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, SVB Leerink, UBS Group, and Wolfe Research in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:RAPT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Options trading has suddenly become more reliable.
Eagle Publishing
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press